AZN/BMY acquisition of Amylin – A step towards leadership in diabetes space

Name: AZN/BMY acquisition of Amylin – A step towards leadership in diabetes space
Brand: MP Advisors
SKU: A92234D5072EN
Price: 90 USD
Availability: InStock

June 2012 | 2 pages | ID: A92234D5072EN
MP Advisors

US$ 90.00

E-mail Delivery (PDF), Online Subscription, E-mail Delivery (Word)

Download PDF Leaflet

Wire Transfer

Checkout Later

Need Help? Ask a Question

Abstracts
Contents

Amylin, Acquisition, BMY, AZN, Bydureon, Byetta, GLP-1 agonists, Type 2 Diabetes, Dulaglutide

COMPANIES MENTIONED

Bristole -Myers, Astrazeneca, Amylin

AZN/BMY acquisition of Amylin – A step towards leadership in diabetes space

More Publications

Need Help?

Ask a Question

Market Reports